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Results: Out of 108 patients treated with radio (chemo) 
therapy, 76 patients had HPV 16 positivity, 24 HPV 16 & 18, 1 
patient HPV 18 while 6 patients were HPV 16 & 18 negative. 
The mean HPV 16 and HPV 18 viral load was 9.3x106 
copies/10ng DNA and 1.3x106 copies/10 ng DNA respectively. 
At 5 months post treatment, 96 patients had complete 
response, 9 had residual/ recurrent local disease and 3 had 
distant relapse. There was significant reduction in HPV viral 
load at treatment completion, 2 and 5 months post 
treatment in complete responders (p 
Conclusions: A significant reduction in HPV 16 and 18 viral 
load occurs in complete responders after completion of 
radical radio (chemo) therapy. However, further correlation 
between persistence or re-infection of HPV and local 
recurrence is ongoing in this prospective study.  
   
OC-0493   
Head and neck cancer HPV16 variant analysis, HPV E2 
variations and E2 protein disruption as radiation sensitivity 
biomarker 
D. Blakaj1, S. Walston1, Z. Chen2, M. Garg3, C. Guha3, S. 
Kalnicki3, R.V. Smith4, R.D. Burk2, N.F. Schlecht5, B. Kumar6, 
M. Old6, T. Teknos6, A. Chakravarti1 
1OSU Medical Center - James Cancer Hospital, Radiation 
Oncology, Columbus Ohio, USA  
2Montefiore Einstein Center for Cancer Care, Pediatrics 
(Genetics), Bronx New York, USA  
3Montefiore Einstein Center for Cancer Care, Radiation 
Oncology, Bronx New York, USA  
4Montefiore Einstein Center for Cancer Care, Otolaryngology, 
Bronx New York, USA  
5Montefiore Einstein Center for Cancer Care, Epidemiology, 
Bronx New York, USA  
6OSU Medical Center - James Cancer Hospital, 
Otolaryngology, Columbus Ohio, USA  
 
Purpose/Objective: Head and neck squamous cell carcinoma 
(HNSCC) associated with HPV has improved response to 
radiation therapy compared to HPV non-associated SCC. 
However, despite this, examples of local failures within 
HNSCC are beginning to emerge. This work aims to 
understand and describe risk factors to radiation resistance 
and increased virulence. HPV-16 non-European (NE) variants 
have been shown to have an 11-fold increased association 
with cervical cancer diagnosis than the European (E) variants. 
Materials and Methods: Our initial analysis of 43 HPV-16 
positive human tumors with PCR that E variants were more 
likely associated with higher stage and lymph node positive 
disease. E2 sequencing was completed for a subset of HPV 16 
variants and analized. The presence of intact E2 DNA has 
shown improved local control and a trend for improved 
disease free survival, for head and neck cancer and cervical 
cancer respectively. To test this, we evaluated five head and 
neck SCC cell lines for presence of intact E2 DNA and mRNA 
using E2 PCR primers. Clonogenic survival assays were 
completed and colony formation was determined. 
Results: E variants were detected more often in higher stage 
HNSCC (79% stage IV v 57% stage I-III, p=0.160) and were also 
more prevalent in node positive disease (82% v 53%, p=0.074). 
Additional tumor HPV 16 variant sequencing needs to be 
completed to more statistical power to detect differences in 
virulence and presentation of malignancy. The subset of 
cancer tissue variant E2 sequencing revealed variation within 
areas know to bind p53 and may affect apoptosis. H&N 
cancer cell line E2 DNA and mRNA expression was confirmed 
and results reveal that E2 disrupted or absent cell lines were 
significantly more radioresistant than their counterparts.  
Conclusions: Preliminary evidence suggests that HPV 16 
variants may be a important factor in evaluation and risk 
stratification. In addition, E2 may serve as a useful tool to 
determine which patients harbor tumors that are 
radioresistant in HPV-positive HNSCC and has implications for 
tumor specific cancer treatments.  
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It is a general belief that patients with oliometastases 
benefit from local ablation of the metastases. Large 
retrospective cohort studies have shown favorable survival 
outcome after surgical resection and radiofrequency 
ablation. Stereotactic body radiation therapy (SBRT) is 
increasingly used for this purpose. Unfortunately, the 
evidence for the use of SBRT of metastases is limited to 
relatively small retrospective studies often with patients with 
various histological types. Colorectal carcinoma (CRC) 
metastasis are often treated with surgery and RFA and it is 
one of the indication where we have the best published 
experience with SBRT.  
A large cohort of CRC patients with metastases primarily in 
the lungs and liver treated with SBRT was published recently 
(1). This study demonstrated promising survival rates of 77, 
33 and 15% at 1, 3 and 5 years after SBRT in a cohort of 
patients who had already received other treatments for 
metastatic disease. Multivariate analysis revealed that WHO 
performance status (0-1) solitary metastasis and small size of 
metastasis (≤ 30 mm) were significantly related to favorable 
survival. The survival of metastatic CRC did not significantly 
differ from the survival of non-CRC metastases patients 
treated with SBRT and the analysis did not identify any tumor 
type with a more favorable outcome when metastases were 
treated with SBRT. 
In general, the approach to metastatic CRC has become more 
aggressive. A number of specialties offer therapies for 
patients with liver oligo-metastases and a multidisciplinary 
team approach in the management of these patients is highly 
important. SBRT may be utilized for a group of patients who 
cannot be treated with surgery. 
 There is sufficient data demonstration that SBRT can be used 
in therapy of CRC metastases, but there is a great need for 
randomized clinical trials to prove the efficacy of SBRT in 
treatment of oligo-metastases and for trials to explore the 
need for systemic therapy along with SBRT. 
Reference:  
1. Mette Marie Fode, Morten Høyer: Survival and 
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stereotactic body radiotherapy for oligo-
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